A Phase II Trial of Single-agent Cetuximab Dose Escalated to Rash in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma

Inclusion Criteria:

- subjects must have recurrent or persistent epithelial ovarian or primary peritoneal
carcinoma. Histologic confirmation of the original primary tumor is required.

- EGFR expression must be positive as determined by an outside reference lab

- Subjects must have had a treatment-free interval following platinum of <12 mos

- All subjects must have measurable disease at baseline

- Subjects must have at least one recurrent lesion to be used to assess response

- Recovery from effect of recent surgery, radiotherapy or chemotherapy

Exclusion Criteria:

- Subjects with other invasive malignancies (including peritoneal mesotheliomas)

- Subjects with unstable cardiac disease or MI within 6 mos

- Subjects with Acute hepatitis

- Subjects with active or uncontrolled infection

- A history of prior cetuximab or other therapy which targets the EGFR pathway or prior
history of prior chimerized or murine monoclonal antibody therapy